Top Markets
Coin of the day
Crossject Société Anonyme Crossject Société Anonyme

Crossject Société Anonyme

ALCJ
Rang in aandelen #12697
Crossject Société Anonyme develops needle-free injection systems. The company... Crossject Société Anonyme develops needle-free injection systems. The company develops ZENEO, a needle-free, prefilled, and single-use auto-injector. Its clinical stage drugs comprise Sumatriptan, which is used for of treatment migraines and cluster headaches; Adrenaline for treating anaphylactic shock; Hydrocortisone that is used for treatment of acute adrenal crisis; Midazolam for treating epileptic seizure; Naloxone used for treatment of overdose; Apomorphine, for treating temporary paralysis in parkinson's disease; Methotrexate used for treatment of rheumatoid arthritis; and Terbutaline, for treating severe asthma crisis. The company was founded in 1997 and is based in Dijon, France.
Aandeelprijs
$2.04
Marktkapitalisatie
$122.58M
Verandering (1 dag)
4.48%
Verandering (1 jaar)
-1.05%
Land
FR
Handel Crossject Société Anonyme (ALCJ)

Categorie

P/S-ratio voor Crossject Société Anonyme (ALCJ)
P/S-ratio op July 2026 TTM: 71.80
Volgens de meest recente financiële rapporten en aandelenkoers van Crossject Société Anonyme is de huidige P/S-ratio (TTM) 71.80. Eind 2023 had het bedrijf een P/S-ratio van 1.26K.
P/S-ratiohistoriek voor Crossject Société Anonyme van 2010 tot 2026
P/S-ratio aan het einde van elk jaar
Jaar P/S-ratio Wijzigen
2026 (TTM) 71.80 194.15%
2024 24.41 -98.06%
2023 1.26K 911.76%
2022 124.63 55.54%
2021 80.13 434.26%
2020 15.00 -83.59%
2019 91.39 1,279.32%
2018 6.63 -47.30%
2017 12.57 -44.75%
2016 22.76 -47.42%
2015 43.28 8.99%
2014 39.71 -21.42%
2013 50.54 -54.97%
2012 112.23 83.88%
2011 61.03 -69.23%
2010 198.36 0.00%
P/S-ratio voor vergelijkbare bedrijven of concurrenten
Bedrijf P/S-ratio Verschil in P/S-ratio Land
13.31 -81.46%
US
2.65 -96.31%
FR
4.46 -93.79%
DE
9.16 -87.24%
JP
2.57 -96.43%
US